ZLX-1

ZLX-1 is an investigational insomnia therapy being developed by Blake Insomnia Therapeutics as a patent‑pending compound aimed at treating sleep disorders without the next‑day residual effects and other side effects that limit current insomnia drugs.[7][10] Publicly available information characterizes ZLX-1 as a novel small-molecule candidate for insomnia, but detailed target, receptor pharmacology, and full mechanistic data have not been disclosed; company communications emphasize efficacy in preclinical or early clinical testing with an improved tolerability profile relative to existing hypnotics.[7][10]

Brand names

Zleepax